a-Synuclein is central to the Lewy body neuropathology of Parkinson's disease (PD), a devastating neurodegenerative disorder characterized by numerous motor and non-motor manifestations. The cardinal motor symptoms are linked to death of dopaminergic neurons in the nigrostriatal pathway. Here we ask why these neurons are preferentially susceptible to neurodegeneration in PD and how a-synuclein is involved. To address these questions we bring together recent findings from genome-wide association studies, which reveal the involvement of a-synuclein gene variants in sporadic PD, with recent studies highlighting important roles for a-synuclein in synaptic transmission and dopaminergic neuron physiology. These latest advances add to our understanding of PD etiology and provide a central link between the genetic findings and neurodegeneration observed in sporadic PD. Introduction PD is a progressive and devastating neurodegenerative disorder, affecting 1% of individuals over 60 years old [1]. The three cardinal clinical features of PD are rigidity, resting tremor and bradykinesia, and these occur when approximately 50% of dopaminergic neurons projecting from the substantia nigra pars compacta (SNc) to the striatum are lost [1]. The neuropathological hallmark of the disease is the presence in surviving SNc neurons of intracellular inclusions known as Lewy bodies (LBs), which are composed mainly of the protein a-synuclein (Box 1) [1,2]. The pathology of PD is not solely confined to the nigrostriatal pathway because LBs are also found in the cortex, amygdala, locus coeruleus and peripheral autonomic system [3,4]. Dysfunction of these extranigral neuronal populations and the presence of LBs correlate with the non-motor manifestations of PD, including autonomic, sleep and olfactory dysfunctions, and these can precede the appearance of motor symptoms [3,4]. Although there is increasing awareness of the importance of these non-motor symptoms, the nigrostriatal dopaminergic pathway remains a focus for research and therapeutic intervention in treating the debilitating motor symptoms of PD.
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PD is an excellent example of a neurological disorder in which a complex mix of aging, genetic susceptibility and environmental insult converge to varying degrees along a spectrum to cause neurodegeneration and disease. At the extreme genetic end of the spectrum is familial PD caused by mutations in one of twelve known loci that together constitute 10% of PD cases [5] . At the extreme environmental-exposure end are a few cases of PD associated with the potent neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [6] . However, it is likely that the majority of sporadic PD cases result from a complex interaction between genes and environment, played out against the background of age, which remains the greatest risk factor. A multiple-hit hypothesis has recently been proposed for dopaminergic neuron loss in PD [7] , suggesting the preferential neuronal death results from a combination of toxic cellular insults, from mitochondrial dysfunction or dopamine oxidation, and an impaired stress-induced protective response. Here we discuss the latest research on the contribution of a-synuclein to dopaminergic neurodegeneration in PD, bringing together recent genetic evidence supporting the involvement of a-synuclein gene variants in PD etiology with key findings emphasizing the role of a-
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Glossary
Genome-wide association studies (GWAS): a powerful approach to identify common genetic variants of weak effect that underlie the risk of common disease. A GWAS is a case-control genetic association study scanning across the entire genome using densely distributed genetic markers to compare genetic variation between affected and unaffected individuals. Stringent statistical correction procedures, such as the Bonferroni correction for multiple testing, are generally adopted when analyzing the GWAS data, and P values <5 Â 10 À8 are required to cross the rigorous threshold for genome-wide significance. The effect of allelic association with disease is measured by the odds ratio (OR). When comparing alleles in cases and controls, an OR of 1 implies that the allele is equally likely to occur in both groups; an OR >1 implies that, for a given SNP, one of the alleles is more likely to be found in the case group than in the controls. Lewy bodies (LBs): the pathological hallmark of PD. These structures are intracytoplasmic eosinophilic spherical bodies with a dense core surrounded by a halo, composed mainly of a-synuclein. LBs also contain many other components, for example ubiquitin, neurofilament proteins and the Alzheimer's disease associated proteins amyloid precursor protein and A-beta peptides. Linkage disequilibrium (LD): a non-random association of alleles at different loci. Two alleles are in LD if they occur together with frequencies significantly different from those predicted from their individual allele frequencies. In other words, LD describes the tendency for a particular set of polymorphisms to avoid recombination and remain together during meiosis, and usually indicates that the two alleles of the SNP are physically close on the DNA. Paired-pulse depression (PPD): a phenomenon observed at dopaminergic terminals (and other synapses) during electrical stimulation of release using close pairs of stimulus pulses. Briefly, dopamine release is less (i.e. depressed) at a second stimulus pulse than after a first pulse.
Single nucleotide polymorphism (SNP): a DNA sequence variation which occurs at a single base pair in the genome and is present in >1% of the population, although SNPs used in GWAS typically have a minor allele frequency of >5%. 
